Buy Mphasis; target of Rs 3079: Anand Rathi
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓Anand Rathi issued a buy rating for Mphasis with a target price of Rs 3079.
- ✓The company delivered strong Q2FY27 results, showing growth across key sectors like BFS and TMT.
- ✓Management raised its FY27 revenue guidance to low double digits, as AI-led deals and a record pipeline support future growth momentum.
Story at a Glance
- Category
- Indian Markets
- Reported By
- MoneyControl
- Reading Speed
- 2 Minute(s)
- Market Focus
- India Economy
Anand Rathi's research report on Mphasis Mphasis delivered a strong Q2FY27, marking its best sequential cc growth in three years, supported by broad-based traction across BFS (53.3% of revenue, +4.4% q/q cc), Insurance (14.7%, +1.8%) and TMT (19.4%, +9.9%), alongside continued ramp-up of large deal wins. Revenue grew 3.3% q/q and 9.7% y/y in CC, with Direct business growing 3.5% q/q and 11.3% y/y CC. Growth is being supported by a favourable shift in deal composition, with shorter-cycle engagements improving revenue conversion. Net new TCV stood at $466mn (-11.7%), of which 66% (vs. 63% in Q1FY27) was AI-led.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
MoneyControl
Read the full, original unfiltered story directly on the publisher's portal.
This brief is for information only and is not investment advice. ArthNow is not a SEBI-registered investment adviser and does not publish buy or sell recommendations. Original reporting is credited to the publisher named above. Read our editorial policy or report an error.